The CCDC’s GOLD Proven Docking and Virtual Screening Software Integrated with the New Sigmatic Sciences Life Science AI Platform
Sigmatic Sciences Launches SigmaticOS – The Only Complete Lab-in-the-Loop Platform for All Scientists
- Sigmatic Sciences, a Sapio Sciences company, enables scientists to move from copilot to autopilot with true lab-in-the-loop automation with integrated model training.
- SigmaticOS is the only complete lab-in-the-loop platform for all scientists, with 100+ agents for orchestration of in silico workflows and lab automation with full traceability.
- Now with LLM, RLM, RAG and Model Training native in product, wet and dry lab workflows to accelerate discoveries in one place.
“Researchers can now benefit from the CCDC’s GOLD proven docking and virtual screening insights directly within Sigmatic Sciences workflows, enabling wider adoption across multidisciplinary teams. Scientists can run docking studies in the same environment as their experiment planning, data capture, and collaboration tools. This is another step forward for the structural science community, harnessing the power and possibilities of AI to improve productivity in the drug discovery pipeline.” Suzanna Ward, CCDC Executive Director.
Sigmatic Sciences, formerly HelixAI and a proud Sapio Sciences Company, launched the Sigmatic Operating System (SigmaticOS) at the Lab of the Future USA Conference in Boston, Massachusetts. SigmaticOS is the only complete lab-in-the-loop platform for computational and drug discovery research scientists.
The platform is designed to enable life sciences companies to achieve the innovation promise of AI by focusing on insight, not process. AI uptake is at a tipping point in life science R&D organizations, with spending predicted to accelerate from $4 billion in 2025 to $20 billion by 20301. This is already reducing preclinical drug development timelines by up to 40%2 in some instances, and investment in autonomous lab platforms is accelerating sharply.
But the proliferation of R&D AI products and open-source tools in life science R&D3 is leading to confusion and inertia in implementation. Currently biopharma organizations operate with 840+4 applications, often in disconnected silos. R&D teams are also struggling to reap actionable insights from heterogeneous legacy data, and to make it meaningfully connected with in silico learnings.
SigmaticOS enables scientists leading in drug discovery and development to move from copilot to autopilot by providing true lab-in-the-loop automation that connects computational tools, data systems and wet-lab execution into fully automated, traceable pipelines. Keeping the scientist in the loop, SigmaticOS enables researchers to execute iterative feedback loops between in silico models and physical experiments. With 100+ agents across in silico workflows, lab automation, and model training, SigmaticOS delivers enterprise-grade security, data traceability, and compliance for biopharma teams scaling AI from pilots to production. SigmaticOS also enables customers to train machine learning models with their data, augmenting large language model intelligence by creating reference data stores for use in a pipeline to guide and enhance the ability to answer scientific questions. It also fine-tunes agents with data for true lab-in-the-loop automation.
Kevin Cramer, Founder and CEO of Sigmatic Sciences, commented: “Biopharma has an abundance of AI tools but struggles with integration. SigmaticOS, as a Sapio Sciences company, solves this by orchestrating in silico science, lab automation, and model training into one traceable platform – with the ultimate aim of enabling scientists to bring life-changing medicines to patients faster.”
Sigmatic Sciences, formerly HelixAI, is led by an AI-native team with experience from Astellas, McKinsey & Co, and Causaly, supported by leading international healthcare investment advisor, GHO Capital.